Only a day after that Pfizer–Allergan deal was officially terminated, Allegan is ready with a potential $3.3 billion collaboration with …

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

More in Partnership


Samsung Bioepis and Takeda Will Jointly Develop New Biologic Therapies

South Korean technology giant Samsung’s biopharma unit Samsung Bioepis collaborated with the Japanese firm Takeda to develop multiple new biologic ...


Celgene Ties with Chinese BeiGene to Develop Solid Tumor Cancers Treatment

Cancer cells escape immune system attack and grow inside the body by putting brakes on the immune system of the ...


Sun Pharma, NIV Collaborate to Develop Dengue, Chikungunya, Zika Drugs

Over a couple of years, the incidence of dengue and chikungunya has seen a dramatical upsurge in India. The global ...


Cancer Startup Dragonfly Bagged $33 Million from Celgene to Develop Blood Cancer Drugs

Immunotherapy startup, Dragonfly Therapeutics bagged $33 million upfront in collaboration with the American biotech, Celgene. The amount will be used ...

Most Popular


7 New Ideas to Start a Healthcare Business in India (2018)

Highlights Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our ...


Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.

Leave a reply